AR126453A1 - Inhibidores de map4k1 - Google Patents
Inhibidores de map4k1Info
- Publication number
- AR126453A1 AR126453A1 ARP220101849A ARP220101849A AR126453A1 AR 126453 A1 AR126453 A1 AR 126453A1 AR P220101849 A ARP220101849 A AR P220101849A AR P220101849 A ARP220101849 A AR P220101849A AR 126453 A1 AR126453 A1 AR 126453A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- halogen
- optionally substituted
- subject
- Prior art date
Links
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title abstract 4
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 12
- 125000005913 (C3-C6) cycloalkyl group Chemical class 0.000 abstract 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 3
- -1 C(O)Me Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910021386 carbon form Inorganic materials 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, caracterizado porque: A¹ se selecciona entre N y CH; A² se selecciona entre CH y N; X se selecciona entre alquilo C₁₋₃, OR³, NHR⁴ y halógeno; B se selecciona entre CR⁵ y N, Y es CR⁶, o Y y B, tomados conjuntamente, forman un heterociclo de 5 a 7 miembros o un cicloalquilo C₅₋₆, donde dicho heterociclo o cicloalquilo son opcionalmente sustituidos por 1 - 6 R⁷; R¹ y R² cada uno se selecciona independientemente entre hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquilo C₁₋₆ sustituido con OR⁸, fenilo, cicloalquilo C₃₋₆ y heterociclo de 4 a 6 miembros, o R¹ y R², tomados junto con los átomos a los que se acoplan, forman un cicloalquilo C₃₋₆ o un heterociclo de 4 a 6 miembros; R³ se selecciona entre alquilo C₁₋₃, cicloalquilo C₃₋₆ y heterociclo de 4 a 6 miembros, donde dicho alquilo, cicloalquilo y heterociclo son opcionalmente sustituidos por 1 - 3 R⁹; R⁴ se selecciona entre hidrógeno, alquilo C₁₋₃, cicloalquilo C₃₋₅ y heterociclo de 4 a 6 miembros, donde dicho alquilo, cicloalquilo y heterociclo son opcionalmente sustituidos por 1 - 3 R¹⁰; R⁵ se selecciona entre hidrógeno, COOH, CN, halógeno y alcoxi C₁₋₃; R⁶ se selecciona entre alquilo C₁₋₅, cicloalquilo C₄₋₆, heterociclo de 3 a 6 miembros, NHR¹¹, NR¹²R¹³ y OR¹⁴, donde dicho alquilo, cicloalquilo o heterociclo son opcionalmente sustituidos por OH, NH₂, 1 - 4 halógeno o R¹⁵, cada R⁷ se selecciona independientemente entre alquilo C₁₋₃, halógeno y OH, donde dicho alquilo es opcionalmente sustituido por 1 - 3 halógeno, o dos R⁷ unidos al mismo carbono forman un oxo, o dos R² unidos al mismo átomo de carbono tomados junto con el átomo de carbono al que se acoplan forman cicloalquilo C₃₋₅; R⁸ es H o alquilo C₁₋₃. cada R⁹ se selecciona independientemente entre alquilo C₁₋₃, cicloalquilo C₃₋₆ sustituido por halógeno, halógeno, C(O)Me, SO₂Me, C(O)NR¹⁶R¹⁷, alcoxi C₁₋₃ y OH; cada R¹⁰ se selecciona independientemente entre alquilo C₁₋₃, cicloalquilo C₃₋₆ sustituido por halógeno, halógeno, SO₂Me, C(O)NR¹⁶R¹⁷, alcoxi C₁₋₃ y OH; R¹¹ se selecciona entre alquilo C₁₋₆ y cicloalquilo C₃₋₆, donde dicho alquilo o cicloalquilo es opcionalmente sustituido por 1 - 3 R¹⁸; R¹² y R¹³ se seleccionan cada uno independientemente entre alquilo C₁₋₆ y cicloalquilo C₃₋₆, donde dicho alquilo o cicloalquilo son opcionalmente sustituidos por 1 - 3 R¹⁸; R¹⁴ se selecciona entre alquilo C₁₋₆ y cicloalquilo C₃₋₆, donde dicho alquilo o cicloalquilo es opcionalmente sustituido por 1 - 3 R¹⁸; R¹⁵ es OH, alquilo C₁₋₃ o cicloalquilo C₃₋₅; R¹⁶ y R¹⁷ se seleccionan cada uno independientemente entre alquilo C₁₋₆ y cicloalquilo C₃₋₆, donde dicho alquilo o cicloalquilo son opcionalmente sustituidos por 1 - 3 R¹⁹; cada R¹⁸ es independientemente halógeno; y cada R¹⁹ es independientemente halógeno. Reivindicación 24: Un método para inhibir la MAP4K1 en un sujeto que lo necesita, caracterizado porque comprende contactar a la MAP4K1 con una cantidad eficaz del compuesto de una cualquiera de las reivindicaciones 1 a 22 o una sal farmacéuticamente aceptable de este, o la composición farmacéutica de la reivindicación 23. Reivindicación 25: Un método para mejorar una respuesta inmunitaria en un sujeto que lo necesita, caracterizado porque comprende administrar al sujeto una cantidad eficaz del compuesto de una cualquiera de las reivindicaciones 1 a 22 o una sal farmacéuticamente aceptable de este o la composición farmacéutica de la reivindicación 23. Reivindicación 26: Un método para tratar un trastorno o enfermedad dependiente de MAP4K1 en un sujeto que lo necesita, caracterizado porque comprende administrar al sujeto una cantidad eficaz del compuesto de una cualquiera de las reivindicaciones 1 a 22 o una sal farmacéuticamente aceptable de este o la composición farmacéutica de la reivindicación 23.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222341P | 2021-07-15 | 2021-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126453A1 true AR126453A1 (es) | 2023-10-11 |
Family
ID=82839174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101849A AR126453A1 (es) | 2021-07-15 | 2022-07-14 | Inhibidores de map4k1 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240336630A1 (es) |
| CN (1) | CN117940406A (es) |
| AR (1) | AR126453A1 (es) |
| TW (1) | TW202321238A (es) |
| WO (1) | WO2023288264A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| ME02461B (me) | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| DK2335427T3 (da) | 2008-09-10 | 2012-06-18 | Widex As | Fremgangsmåde til lydbehandling i et høreapparat og et høreapparat |
| CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| DK2614082T3 (en) | 2010-09-09 | 2018-11-26 | Pfizer | 4-1BB BINDING MOLECULES |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| CN103608040B (zh) | 2011-04-20 | 2017-03-01 | 米迪缪尼有限公司 | 结合b7‑h1和pd‑1的抗体和其他分子 |
| SI2785375T1 (sl) | 2011-11-28 | 2020-11-30 | Merck Patent Gmbh | Protitelesa proti PD-L1 in uporabe le-teh |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2020023551A1 (en) * | 2018-07-24 | 2020-01-30 | Genentech, Inc. | Naphthyridine compounds and uses thereof |
| WO2021133809A1 (en) * | 2019-12-23 | 2021-07-01 | Blueprint Medicines Corporation | Inhibitors of mutant forms of egfr |
| JP2023510918A (ja) * | 2020-01-15 | 2023-03-15 | ブループリント メディシンズ コーポレイション | Ｍａｐ４ｋ１阻害剤 |
-
2022
- 2022-07-14 AR ARP220101849A patent/AR126453A1/es unknown
- 2022-07-14 TW TW111126410A patent/TW202321238A/zh unknown
- 2022-07-14 US US18/578,926 patent/US20240336630A1/en active Pending
- 2022-07-14 WO PCT/US2022/073718 patent/WO2023288264A1/en active Application Filing
- 2022-07-14 CN CN202280062105.2A patent/CN117940406A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202321238A (zh) | 2023-06-01 |
| CN117940406A (zh) | 2024-04-26 |
| US20240336630A1 (en) | 2024-10-10 |
| WO2023288264A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115646A1 (es) | Inhibidores de quinasas dependientes de ciclinas | |
| AR124369A1 (es) | Inhibidores de prmt5 novedosos | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR088781A1 (es) | Compuestos antimicrobianos y metodos para prepararlos y utilizarlos | |
| AR103969A1 (es) | Inmunomoduladores | |
| AR103182A1 (es) | Inmunomoduladores | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103934A1 (es) | Derivados de benzimidazoles como inhibidores de bromodominio | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR117424A1 (es) | Inhibidores de los receptores erbb | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR113886A1 (es) | Derivados de indol macrocíclicos | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| AR109487A1 (es) | Derivados de imidazo-2-il-piridin-2-ona como inhibidores de la unión de las proteínas bet | |
| AR126108A1 (es) | Tratamientos para la degradación del braf mutante | |
| AR097403A1 (es) | Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación | |
| AR128212A1 (es) | Composiciones y métodos para la inhibición de ras |